Diamedica Therapeutics Inc. (DMAC) — 10-Q Filings
All 10-Q filings from Diamedica Therapeutics Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
DiaMedica's Net Loss Widens on Soaring R&D Costs
— Nov 12, 2025 Risk: high
DiaMedica Therapeutics Inc. (DMAC) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $24.026 million, up from $ -
DiaMedica's Q2: No Revenue, R&D Flat, Private Placement Boosts Capital
— Aug 12, 2025 Risk: high
DiaMedica Therapeutics Inc. reported no revenue for the six months ended June 30, 2025, consistent with the prior year. The company's net loss for the six month -
DiaMedica Therapeutics Q1 2025 10-Q Filed
— May 13, 2025 Risk: medium
DiaMedica Therapeutics Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company, focused on pharmaceutical preparat -
DiaMedica Therapeutics Files Q3 2024 10-Q
— Nov 13, 2024 Risk: medium
DiaMedica Therapeutics Inc. filed its Q3 2024 10-Q report on November 13, 2024, covering the period ending September 30, 2024. The company, previously known as -
DiaMedica Therapeutics Q2 2024 Update
— Aug 7, 2024 Risk: medium
DiaMedica Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $27.1 million as of June 30, 2 -
DiaMedica Therapeutics Inc. Files 10-Q for Q1 2024
— May 8, 2024 Risk: low
DiaMedica Therapeutics Inc. (DMAC) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. DiaMedica Therapeutics Inc. filed its Q1 2024 10-Q report on May
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX